All In Biotech

NDA 021117 · Hospira

Calcium Chloride 10% In Plastic Container

Calcium Chloride · Injection

Last checked: Nov 20, 2026Latest source record: May 11, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Jan 28, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

3,113

2,812 serious, 734 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 27, 2026.

Calcium Chloride Injection is indicated for the treatment of adult and pediatric patients with acute symptomatic hypocalcemia. Limitations of Use The safety and effectiveness of Calcium Chloride Injection for long-term use has not been established. Calcium Chloride Injection is a form of calcium indicated for the treatment of adult and pediatric and patients with acute symptomatic hypocalcemia. (1) Limitations of Use: The safety and effectiveness of Calcium Chloride Injection for long-term use has not been established.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 28, 2000 Original approval · Type 3 - New Dosage Form ReviewLetter
1 products under this application
  • CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER · CALCIUM CHLORIDE 100MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain434
  • drug ineffective425
  • injury414
  • nausea358
  • off label use336
  • anxiety295
  • renal failure276
  • pyrexia274
  • dyspnoea254
  • hypotension251
  • condition aggravated242
  • pemphigus230

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200511
200631
2007584
200830
200921
201046
2011240
201284
201332
201468
201541
201653
201786
2018137
2019135
2020162
2021159
2022190
2023246
2024315
2025249
2026179

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.